PTEN and triple-negative breast carcinoma: For example, a recent study combining the treatment of G-protein-coupled receptor (PAR1), EGFR signaling, and PI3Kβ inhibitor,137 and another study combining PI3Kβ inhibitor with paclitaxel (a chemotherapeutic agent) and anti-PD1,138 suggested that these combinations could be new potential therapeutic strategies for PTEN-inactive triple-negative breast cancer (TNBC).